Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 5/20 | 0.45 |
| ▸ | S1PR2 | O95136 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | UBE2M | P61081 | 2/20 | 0.42 |
| ▸ | DCUN1D1 | Q96GG9 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | ACP1 | P24666 | 1/20 | 0.40 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.40 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1575317 | 0.90 | GRIN2B (0.46) | GRIN2BS1PR2MAPTLMNAALDH1A1 | |
| SCHEMBL1575048 | 0.89 | GRIN2B (0.46) | GRIN2BS1PR2MAPTLMNAACP1 | |
| SCHEMBL1574907 | 0.88 | GRIN2B (0.57) | GRIN2BMAPTUBE2MDCUN1D1LMNA | |
| SCHEMBL1574842 | 0.85 | S1PR2 (0.41) | GRIN2BS1PR2UBE2MDCUN1D1LMNA | |
| SCHEMBL1575193 | 0.84 | ALDH1A1 (0.47) | GRIN2BS1PR2MAPTUBE2MDCUN1D1 | |
| SCHEMBL1575134 | 0.83 | MAPT (0.46) | MAPTUBE2MDCUN1D1LMNA | |
| SCHEMBL1574527 | 0.83 | GRIN2B (0.49) | GRIN2BUBE2MDCUN1D1LMNATRPA1 | |
| SCHEMBL1575005 | 0.83 | GRIN2B (0.49) | GRIN2BS1PR2MAPTLMNAPAK1 | |
| SCHEMBL1575579 | 0.82 | NPSR1 (0.51) | GRIN2BMAPTLMNAALDH1A1 | |
| SCHEMBL1575081 | 0.80 | GRIN2B (0.50) | GRIN2BMAPTLMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2308562-A2 | Azetidine ring compounds and drugs comprising the same | Ono Pharmaceutical Co., Ltd. (JP) | 2011-04-13 | — | — | EP | disclosed |
| US-7511159-B2 | Azetidine ring compounds and drugs comprising the same | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-03-31 | — | — | US | disclosed |
| US-20070135402-A1 | Azetidine ring compounds and drugs comprising the same | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-06-14 | — | — | US | disclosed |
| EP-1698375-A1 | AZETIDINE RING COMPOUNDS AND DRUGS COMPRISING THE SAME | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-09-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135402-A1 | Azetidine ring compounds and drugs comprising the same | EDNRA, LIPG, EDNRB | GRIN2B 3001/4885S1PR2 937/4885MAPT 3908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.